Patent ID: 7838635
Filing Date: 2010-11-23
Classification: A61K,A61P,C07K

Abstract:
1. An isolated anti-CD16A antibody or antigen binding fragment thereof comprising a V H CDR1 having the sequence of SEQ ID NO:35, a V H CDR2 having the sequence of SEQ ID NO:39, a V H CDR3 having the sequence of SEQ ID NO:59, a V L CDR1 having the sequence of SEQ ID NO:67, a V L CDR2 having the sequence of SEQ ID NO:75, and a V L CDR3 having the sequence of SEQ ID NO:88, wherein at least one of said CDRs has one or more amino acid modifications selected from the group consisting of, in the V H domain, a Val at position 34 in CDR1; a Leu at position 50 in CDR2; a Phe at position 52 in CDR2; an Asn at position 54 in CDR2; a Ser at position 60 in CDR2; a Ser at position 62 in CDR2; a Tyr at position 99 in CDR3; an Asp at position 101 of CDR3; and, in the V L domain, an Arg at position 24 in CDR1; a Ser at position 25 in CDR1; a Tyr at position 32 in CDR1; a Leu at position 33 in CDR1; an Ala at position 34 in CDR1; an Asp, Trp or Ser at position 50 in CDR2; an Ala at position 51 in CDR2; a Ser at position 53 in CDR2; an Ala or Gln at position 55 in CDR2; a Thr at position 56 in CDR2; a Tyr at position 92 in CDR3; a Ser at position 93 in CDR3; and a Thr at position 94 in CDR3, and wherein said positions are according to Kabat.